CONCLUSIONS: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp&Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).